Developer docs
API playgroundTry for free, no card

Search company profiles

Synnovis Group

Full company profile

uuid006gv3f

Namestring
Synnovis Group
Legal namestring
Synnovis Group LLP
Websiteurl
synnovis.co.uk
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical pathology services, diagnostic laboratory services, medical testing services, blood sciences diagnostics, NHS pathology partner
Industry3 codes
1Central Laboratory Services (Core Lab Operations)
CodeHLAGAEAAPrimaryYes
2Anatomic Pathology (Histopathology & Cytopathology)
CodeHLAFAMAAPrimaryNo
3Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
CodeHLAAALACPrimaryNo
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Diagnostic Pathology Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1NHS Pathology Services
TypeManaged Services
Description

Synnovis provides comprehensive pathology and diagnostic services to NHS trusts under long-term partnership agreements. The organization is jointly owned by SYNLAB UK & Ireland, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust.

synnovis.co.uk
2Specialist Diagnostic Testing
TypeSubscription Recurring
Description

Provision of specialized diagnostic testing including liquid biopsy cancer testing, genomic analysis, and specialized reference laboratory services to NHS and private healthcare providers.

scientistlive.com
3Consumables Supply
TypeTransaction Fee
Description

Supply of pathology consumables including specimen collection kits and transportation bags to GP practices through an online ordering portal.

synnovis.co.uk
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Synnovis Group is the UK's leading pathology organization, operating as a joint venture between SYNLAB UK & Ireland, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust. The company delivers comprehensive diagnostic pathology services through a hub-and-spoke model centered at the Blackfriars Hub in London, processing 22.5 million tests annually across 60+ routine and specialist laboratories covering Blood Sciences, Haematology, Microbiology, Virology, Histopathology, Clinical Transplantation, Genetics, and Newborn Screening. Services are commissioned to NHS secondary care trusts, primary care GP practices, and private healthcare providers across South East London and beyond.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 22.5 million tests processed in past 12 months with volume doubling year on year
+3 more records
Product overview1 text field

Synnovis Group is the UK's leading pathology organisation operating as a joint venture between SYNLAB UK & Ireland, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust. Established in 2021 to transform pathology services in South East London, Synnovis delivers comprehensive diagnostic pathology services through a hub-and-spoke model centered at its state-of-the-art Blackfriars Hub facility. The company's portfolio includes AI-powered liquid biopsy testing via the MSK-ACCESS® partnership with SOPHiA GENETICS, advanced digital pathology technology, and over 60 routine and specialist laboratories covering Blood Sciences, Haematology, Clinical Biochemistry, Microbiology, Virology, Infection Sciences, Genetics, Histopathology, Clinical Transplantation, Haemostasis and Thrombosis, Diagnostic Immunology, Precision Medicine, and Newborn Screening. The Blackfriars Hub processes approximately 70% of the organisation's 22.5 million annual tests and serves nearly two million patients.

Product and service14 records
1MSK-ACCESS Liquid Biopsy Testing
CategorySpecialist Diagnostic Testing
Description

AI-powered blood-based diagnostic test that analyzes circulating tumor DNA from a simple blood draw to detect actionable genomic alterations for lung and breast cancer patients, enabling targeted therapy selection up to two weeks earlier. Offered under partnership with SOPHiA GENETICS using SOPHiA DDM AI platform.

2Virology Services
CategoryLaboratory Diagnostic Services
Description

Full specialist virology service including high-throughput molecular diagnostics, viral load testing, sequencing, genotyping, and antiviral resistance analysis for HIV, hepatitis viruses, respiratory viruses, and emerging pathogens. UKAS-accredited medical laboratory (No. 8640) to ISO 15189:2022.

3Haematology and Coagulation Services
4Clinical Biochemistry Services
5South East Haematological Malignancy Diagnostic Service (SE-HMDS)
6Precision Medicine Laboratory
7Regional Newborn Screening Laboratory
8Microbiology Services
9Clinical Transplantation Laboratory
10Diagnostic Immunology Laboratory
11Haemostasis and Thrombosis Services
12Histopathology Services
13Infection Sciences
14Drugs of Abuse Testing
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1SOPHiA GENETICS
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Partnership to deliver MSK-ACCESS liquid biopsy testing (powered by SOPHiA DDM AI technology) for lung and breast cancer patients across the UK as part of NHS England's 'blood test-first' program. The blood-based test analyzes circulating tumor DNA from a simple blood draw and can help fast-track patients to targeted therapy up to two weeks earlier. Synnovis is already supporting approximately 400 patients per month and anticipates testing roughly 7,000 breast and lung cancer patients annually, representing about one-third of all ctDNA tests in England.

2Guy's and St Thomas' NHS Foundation Trust
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint venture partner in Synnovis providing NHS pathology services. Synnovis operates as a pathology partnership between SYNLAB UK & Ireland, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust, established in 2021 to transform pathology services in South East London.

3King's College Hospital NHS Foundation Trust
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint venture partner in Synnovis providing NHS pathology services. Synnovis operates as a pathology partnership between SYNLAB UK & Ireland, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust, established in 2021 to transform pathology services in South East London.

4SYNLAB UK & Ireland
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Parent company and joint venture partner controlling Synnovis operations. Synnovis is a pathology partnership between SYNLAB UK & Ireland, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust.

5Global Services Group (GSG)
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Consumables and logistics partner for Synnovis. GSG handles delivery of pathology consumables including specimen collection kits and transportation bags to GP practices. Orders are processed through the Synnovis online portal with delivery within 5 working days.

6BD (Becton Dickinson)
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Phlebotomy products supplier for Bexley, Greenwich and Lewisham GPs. BD handles ordering and delivery of phlebotomy supplies through dedicated email contacts.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synnovis Group

Diagnostic Pathology Servicessynnovis.co.uk

Synnovis Group firmographics

Firmographics
Name
Synnovis Group
Legal name
Synnovis Group LLP
Website
https://synnovis.co.uk
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

Synnovis Group industry classification

Industry
Product category
Diagnostic Pathology Services
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro primary industry
Central Laboratory Services (Core Lab Operations) (HLAGAEAA)
akta.pro secondary industries
Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA), Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)

Keywords

  • Clinical pathology services
  • Diagnostic laboratory services
  • Medical testing services
  • Blood sciences diagnostics
  • NHS pathology partner

Where Synnovis Group is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices8 records

Markets served

Synnovis Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations

Revenue model

  1. NHS Pathology Services: Synnovis provides comprehensive pathology and diagnostic services to NHS trusts under long-term partnership agreements. The organization is jointly owned by SYNLAB UK & Ireland, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust.
  2. Specialist Diagnostic Testing: Provision of specialized diagnostic testing including liquid biopsy cancer testing, genomic analysis, and specialized reference laboratory services to NHS and private healthcare providers.
  3. Consumables Supply: Supply of pathology consumables including specimen collection kits and transportation bags to GP practices through an online ordering portal.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Synnovis Group product offering

Product offering

Core offering

Synnovis Group is the UK's leading pathology organization, operating as a joint venture between SYNLAB UK & Ireland, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust. The company delivers comprehensive diagnostic pathology services through a hub-and-spoke model centered at the Blackfriars Hub in London, processing 22.5 million tests annually across 60+ routine and specialist laboratories covering Blood Sciences, Haematology, Microbiology, Virology, Histopathology, Clinical Transplantation, Genetics, and Newborn Screening. Services are commissioned to NHS secondary care trusts, primary care GP practices, and private healthcare providers across South East London and beyond.

Product overview

Synnovis Group is the UK's leading pathology organisation operating as a joint venture between SYNLAB UK & Ireland, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust. Established in 2021 to transform pathology services in South East London, Synnovis delivers comprehensive diagnostic pathology services through a hub-and-spoke model centered at its state-of-the-art Blackfriars Hub facility. The company's portfolio includes AI-powered liquid biopsy testing via the MSK-ACCESS® partnership with SOPHiA GENETICS, advanced digital pathology technology, and over 60 routine and specialist laboratories covering Blood Sciences, Haematology, Clinical Biochemistry, Microbiology, Virology, Infection Sciences, Genetics, Histopathology, Clinical Transplantation, Haemostasis and Thrombosis, Diagnostic Immunology, Precision Medicine, and Newborn Screening. The Blackfriars Hub processes approximately 70% of the organisation's 22.5 million annual tests and serves nearly two million patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • MSK-ACCESS Liquid Biopsy Testing AI-powered blood-based diagnostic test that analyzes circulating tumor DNA from a simple blood draw to detect actionable genomic alterations for lung and breast cancer patients, enabling targeted therapy selection up to two weeks earlier. Offered under partnership with SOPHiA GENETICS using SOPHiA DDM AI platform.
  • Virology Services Full specialist virology service including high-throughput molecular diagnostics, viral load testing, sequencing, genotyping, and antiviral resistance analysis for HIV, hepatitis viruses, respiratory viruses, and emerging pathogens. UKAS-accredited medical laboratory (No. 8640) to ISO 15189:2022.
  • Haematology and Coagulation Services
  • Clinical Biochemistry Services
  • South East Haematological Malignancy Diagnostic Service (SE-HMDS)
  • Precision Medicine Laboratory
  • Regional Newborn Screening Laboratory
  • Microbiology Services
  • Clinical Transplantation Laboratory
  • Diagnostic Immunology Laboratory
  • Haemostasis and Thrombosis Services
  • Histopathology Services
  • Infection Sciences
  • Drugs of Abuse Testing

Quantifiable outcome

  • 22.5 million tests processed in past 12 months with volume doubling year on year
  • +3 more outcomes

Companies that use Synnovis Group

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Synnovis Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Synnovis Group partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • SOPHiA GENETICScoreStrategic or Co-development Partner · 13 May 2026Partnership to deliver MSK-ACCESS liquid biopsy testing (powered by SOPHiA DDM AI technology) for lung and breast cancer patients across the UK as part of NHS England's 'blood test-first' program. The blood-based test analyzes circulating tumor DNA from a simple blood draw and can help fast-track patients to targeted therapy up to two weeks earlier. Synnovis is already supporting approximately 400 patients per month and anticipates testing roughly 7,000 breast and lung cancer patients annually, representing about one-third of all ctDNA tests in England.
  • Guy's and St Thomas' NHS Foundation TrustcoreStrategic or Co-development PartnerJoint venture partner in Synnovis providing NHS pathology services. Synnovis operates as a pathology partnership between SYNLAB UK & Ireland, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust, established in 2021 to transform pathology services in South East London.
  • King's College Hospital NHS Foundation TrustcoreStrategic or Co-development PartnerJoint venture partner in Synnovis providing NHS pathology services. Synnovis operates as a pathology partnership between SYNLAB UK & Ireland, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust, established in 2021 to transform pathology services in South East London.
  • SYNLAB UK & IrelandcoreStrategic or Co-development PartnerParent company and joint venture partner controlling Synnovis operations. Synnovis is a pathology partnership between SYNLAB UK & Ireland, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust.
  • Global Services Group (GSG)minorChannel Partner/ Reseller/ DistributorConsumables and logistics partner for Synnovis. GSG handles delivery of pathology consumables including specimen collection kits and transportation bags to GP practices. Orders are processed through the Synnovis online portal with delivery within 5 working days.
  • BD (Becton Dickinson)minorChannel Partner/ Reseller/ DistributorPhlebotomy products supplier for Bexley, Greenwich and Lewisham GPs. BD handles ordering and delivery of phlebotomy supplies through dedicated email contacts.

Scale indicators12 records

Recent moves8 records

Expansion highlights5 records

Synnovis Group competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Synnovis Group social profiles

Digital presence

Synnovis Group compliance and trust

Trust signal

Compliance8 records

Synnovis Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synnovis Group leadership team

Management profile

Number of profiles

Profiles5 records

Synnovis Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synnovis Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synnovis Group

What does Synnovis Group do?

Synnovis Group is the UK's leading pathology organization, operating as a joint venture between SYNLAB UK & Ireland, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust. The company delivers comprehensive diagnostic pathology services through a hub-and-spoke model centered at the Blackfriars Hub in London, processing 22.5 million tests annually across 60+ routine and specialist laboratories covering Blood Sciences, Haematology, Microbiology, Virology, Histopathology, Clinical Transplantation, Genetics, and Newborn Screening. Services are commissioned to NHS secondary care trusts, primary care GP practices, and private healthcare providers across South East London and beyond.

Is Synnovis Group a public or private company?

Synnovis Group is a private company. It is classified as corporate owned and is currently operating.

When was Synnovis Group founded?

Synnovis Group was founded in 2021. It employs 1,001 to 5,000 people.

Where is Synnovis Group based?

Synnovis Group is headquartered in London, United Kingdom, in the Europe region.

How does Synnovis Group make money?

Three revenue lines are on record. NHS Pathology Services are the primary driver. The others are specialist Diagnostic Testing and consumables Supply.

Does Synnovis Group have an API?

No public API is recorded for Synnovis Group.

What industry is Synnovis Group in?

Synnovis Group's product category is Diagnostic Pathology Services. Its primary akta.pro industry code is HLAGAEAA, Central Laboratory Services (Core Lab Operations), with a secondary code of HLAFAMAA, Anatomic Pathology (Histopathology & Cytopathology). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MickaiThe Synnovis Fallout Keeps Growing: Who Should Hold NHS Data?NHS trusts continue disclosing patient records stolen in the 2024 Synnovis Qilin attack, with Bedfordshire Hospitals confirming nearly 33,000 patients affected in June 2026. The author argues clinical data and AI must stay within the trust's perimeter, promoting MICKAI's air-gapped operating system that runs on local hardware with no external connection.PR NewswireSynnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.Synnovis and SOPHiA GENETICS partnered to bring liquid biopsy testing for lung and breast cancer to UK patients via NHS England's blood test-first program. The MSK-ACCESS test, powered by SOPHiA DDM, can fast-track targeted therapy up to two weeks earlier. They expect to test about 7,000 patients annually, roughly one third of all ctDNA tests in England.PharmafileSynnovis and SOPHiA GENETICS expand liquid biopsy testing in NHS cancer careSynnovis and SOPHiA GENETICS announced a collaboration to expand blood-based cancer testing for lung and breast cancer patients across the UK via NHS England's blood test programme. The partnership supports the MSK-ACCESS test, which analyzes circulating tumour DNA, and currently supports about 400 patients monthly, with an estimated 7,000 annual tests. The companies say the approach may shorten treatment decisions by up to two weeks.NewswireSynnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.Synnovis and SOPHiA GENETICS partnered to bring liquid biopsy testing to lung and breast cancer patients across the U.K. under NHS England's blood test-first program. The MSK-ACCESS test, powered by SOPHiA DDM, can fast-track targeted therapy up to two weeks earlier. They anticipate testing about 7,000 patients annually, roughly one third of all ctDNA tests in England.Cyber Security NewsRansomware Attack 2025 Recap – From Critical Data Extortion to Operational DisruptionThe global ransomware landscape in 2025 experienced a stark paradox: attack volumes surged 34-50% with 4,701 confirmed incidents between January and September, yet ransom payment rates collapsed to historic lows of 23-25%, forcing threat actors to fundamentally reimagine their business models and tactics amid a 33% decline in total revenues to $813.6 million. The ecosystem underwent profound fragmentation following law enforcement disruptions, with 85 active ransomware groups now competing for victims compared to fewer dominant operators previously, as double and triple extortion tactics, AI-enhanced phishing, and cloud infrastructure targeting became standard. Critical infrastructure sectors including manufacturing (up 61%), healthcare (293 attacks), energy, transportation, and finance accounted for 50% of all attacks, with the confirmed contribution of the Synnovis ransomware attack to a patient's death illustrating the life-threatening stakes of these cyber threats.Trend MicroWhat Is Healthcare Cybersecurity?The article outlines the cybersecurity challenges facing the healthcare sector, highlighting why it is a prime target for cybercriminals due to valuable patient data and legacy infrastructure. It details specific threats such as ransomware and phishing, while citing major incidents like the Synnovis attack in the UK and the Düsseldorf University Hospital breach in Germany to illustrate operational risks. Additionally, the text reviews regulatory frameworks like GDPR and emerging technological trends including telehealth, cloud computing, and AI.Clifford ChanceCyber Security and Resilience (network and information systems) Bill issued by UK governmentThe UK government published the draft Cyber Security and Resilience (Network and Information Systems) Bill on 12 November 2025 to update the existing NIS Regulations 2018 and address evolving cyber threats to essential services and digital infrastructure. The Bill expands regulatory scope to include Managed Service Providers, data centers, and cloud services, introduces stricter incident reporting requirements with 24-hour initial and 72-hour full notifications, and significantly increases penalties up to £17 million or 4% of global turnover for non-compliance. The proposed legislation follows recent high-profile cyberattacks exploiting supply chain vulnerabilities at companies including Capita, Advanced, MOVEit, and Synnovis, which caused widespread disruption to critical services and compromised data for millions of people.BankInfoSecuritySynnovis Notifying UK Providers of Data Theft in 2024 AttackSynnovis, a UK pathology lab, experienced a ransomware attack in June 2024 that disrupted services and resulted in the theft of patient data. The company completed a forensic review and began notifying affected healthcare providers, with some data including personal details and test results. The attack was attributed to the Russian-speaking group Qilin and caused significant disruptions to healthcare operations and patient care.Trend MicroWhat Is Healthcare Cybersecurity?The article outlines the increasing cybersecurity risks in the healthcare sector, citing valuable patient data and legacy infrastructure as primary drivers for cybercriminal activity. It highlights significant incidents such as the 2024 Synnovis ransomware attack affecting NHS trusts and the 2020 DoppelPaymer incident at a German hospital to illustrate operational disruptions and ethical consequences. The text concludes by recommending specific security solutions and platforms provided by Trend Micro to mitigate these threats.BBCBlood test firm blamed by GPs for 'catalogue of disasters'GPs in south-east London are blaming Synnovis, a blood-testing firm, for unreliable results causing misdiagnoses and unnecessary hospital referrals. The firm, which won a £2bn contract in 2021, has been cited for erroneous potassium levels and processing delays. GPs have lost faith in the service, with concerns escalated to the Integrated Care Board.